Skip to main
  1. Stocks
  2. Zevra Therapeutics Inc
  3. Forecast
ZVRA

ZVRA Stock Forecast & Price Target

ZVRA Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zevra Therapeutics is supported by a stronger-than-expected U.S. commercial thesis for Miplyffa, with claims data and ongoing patient identification suggesting the NPC market may be materially larger than initially assumed. Because Miplyffa is already approved and commercialized in the U.S., the company has a real operating base, is continuing to add patient enrollments, and appears positioned to benefit from a conservatively valued pool of roughly 300-350 diagnosed NPC patients. The setback in Europe reduces near-term optionality, but it does not weaken the core U.S. opportunity, while EU clarity, territory expansion in 3Q, IP extension, and celiprolol development create additional upside drivers into 2026.

Bears say

Zevra Therapeutics is facing a materially weakened fundamental outlook after the EMA reaffirmed its refusal of Meplyffa in NPC, citing concerns about the handling and analysis of the pivotal NPC-002 Phase II/III trial (n=50), lack of clear benefit in ambulation or cognition, and an unconvincing miglustat subgroup effect. The loss of the EU opportunity removes a major upside driver, lowers its approval probability there to 0% from 40%, and strips out EU Miplyffa net sales and related launch costs from FY27E onward, while the probability-adjusted Miplyffa NPV falls to $14/share from $18. Its valuation now depends more heavily on U.S. execution, with FY27E Miplyffa U.S. sales still estimated at $165.0MM and YE26 net cash at $4/share, but the company’s growth case is increasingly concentrated and regulatory risk remains elevated.

ZVRA has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zevra Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

ZVRA Analyst Forecast & Price Prediction

Get the latest ZVRA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ZVRA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zevra Therapeutics Inc (ZVRA) Forecast

Analysts have given ZVRA a Strong Buy based on their latest research and market trends.

According to 7 analysts, ZVRA has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zevra Therapeutics Inc (ZVRA)


ZVRA Analyst Forecast & Price Prediction

Get the latest ZVRA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ZVRA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ZVRA stock data and trends